JPMorgan, Strategy, Citigroup, Rocket Lab, CVS Insider Shock

Insiders have been trading these 5 stocks: ((JPM)), ((MSTR)), ((C)), ((RKLB)) and ((CVS)). Here is a breakdown of their recent trades and their value.

Top executives at JPMorgan Chase sparked attention as insiders moved sizable blocks of stock on the open market. CEO CCB Marianne Lake sold 6,427 shares for $1,917,495, Co-CEO CIB Douglas Petno sold 5,659 shares for $1,697,982, CEO Asset & Wealth Management Mary Erdoes sold 6,648 shares for $1,983,497, and Director Lori Beer sold 3,165 shares for $949,658.

Strategy investors watched closely as Director Jarrod Patten executed a notable insider sale that trimmed his holdings. Patten sold 3,750 shares of Strategy stock in a single transaction, generating proceeds of $713,562 and signaling a meaningful move that may prompt shareholders to review their own positioning.

Citigroup also joined the wave of insider selling, with one board member reducing exposure to the banking giant. Director JOHN CUNNINGHAM DUGAN sold 2,117 shares of Citigroup stock in a transaction valued at $265,260, a development that will be scrutinized for clues about confidence in the company’s near-term outlook.

Rocket Lab USA faced attention from growth investors as a major backer chose to lock in gains after a strong run. Significant shareholder Alexander R Slusky unloaded 100,000 shares of Rocket Lab USA stock, a sizable block worth $11,807,250, raising questions about valuation, risk appetite, and the future trajectory of this space-focused name.

CVS Health rounded out the insider activity as a key executive shifted a substantial portion of equity compensation into cash. EVP, Chief Exp & Tech Officer Tilak Mandadi sold 69,551 shares of CVS Health stock, a transaction totaling $6,230,378, and the move may influence how the market interprets CVS’s strategic technology and experience initiatives.